Author: Rossi, Fabio Henrique
Title: Venous thromboembolism in COVID-19 patients Cord-id: hpndf3l9 Document date: 2020_10_16
ID: hpndf3l9
Snippet: COVID-19 is a potentially serious respiratory disease caused by the SARS-CoV-2 virus that involves an increased risk of venous thromboembolism (VTE). Its pathophysiology is apparently related to an exacerbated inflammatory process and coagulopathy, verified by an increase in D-dimer, fibrinogen, and fibrin degradation products. Occurrence must be monitored, prevented, and treated according to existing recommendations and guidelines. The increased risk of thrombosis, and the association between t
Document: COVID-19 is a potentially serious respiratory disease caused by the SARS-CoV-2 virus that involves an increased risk of venous thromboembolism (VTE). Its pathophysiology is apparently related to an exacerbated inflammatory process and coagulopathy, verified by an increase in D-dimer, fibrinogen, and fibrin degradation products. Occurrence must be monitored, prevented, and treated according to existing recommendations and guidelines. The increased risk of thrombosis, and the association between this phenomenon and the most severe forms of the disease and death have prompted some groups to propose a more aggressive prophylactic and therapeutic approach. However, the risk-benefit profile of this type of conduct has not been defined and cases must be assessed individually, with a multidisciplinary approach. In this study, we review the main studies and evidence available to date on diagnosis, prophylaxis, and treatment of venous thromboembolism in COVID-19 patients.
Search related documents:
Co phrase search for related documents- absolute contraindication and lung disease: 1
- absolute contraindication and lung injury: 1
- absolute risks and acute respiratory failure: 1
- absolute risks and lung disease: 1, 2
- activity time and acute disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activity time and acute respiratory failure: 1, 2
- activity time and lmwh weight heparin: 1, 2
- activity time and low molecular lmwh weight heparin: 1, 2
- activity time and lung disease: 1, 2, 3, 4, 5, 6
- activity time and lung injury: 1, 2, 3, 4
- acute disease and liverpool university: 1
- acute disease and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute disease and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
- acute disease and low molecular lmwh weight heparin prophylaxis: 1
- acute disease and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute disease and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- acute respiratory failure and lmwh weight heparin: 1, 2, 3, 4
- acute respiratory failure and low molecular lmwh weight heparin: 1, 2, 3, 4
- acute respiratory failure and low molecular lmwh weight heparin prophylaxis: 1
Co phrase search for related documents, hyperlinks ordered by date